金太阳国际APP(中国)官方网站-IOS/Android版

2024.01.23

Health Canada approves SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

2023.11.02

SinoT received tentative approval by FDA for Generic Tofacitinib Extended Release Tablet

On August 8, 2023, U.S. Food and Drug Administration（FDA）tentatively approved SinoT’s ANDA application for Tofacitinib Extended Release Tablet (ANDA #216001).

2023.06.05

FDA approves SinoT's ANDA application for PREGABALIN EXTENDED-RELEASE TABLETS

Recently，Food and Drug Administration (FDA) approved SinoT’s ANDA（# 214496）application for PREGABALIN EXTENDED-RELEASE TABLETS（82.5 mg, 165 mg, and 330 mg）

2023.05.15

FDA approves SinoT’s ANDA application for Mesalamine, delayed-release tablets

Recently，Food and Drug Administration (FDA) approved SinoT’s ANDA（#217337）application for Mesalamine, delayed-release tablets（1.2g）.

2022.08.25

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA

2022.08.25

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA

2022.04.07

The generic drug Posaconazole delayed-release tablets (100mg) Regulatory Approval in Singapore

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been granted approval from the Health Sciences Authority (HSA) in Singapore.

2021.11.02

NMPA approves SinoT’s ANDA application for Bupropion (XL)(150mg,300mg)

Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Bupropion hydrochloride extended-release tablets (XL)(150mg,300mg), this product has already been approved in FDA on August 2017.

2021.08.12

FDA approves SinoT’s ANDA application for PAROXETINE HYDROCHLORIDE，Extended-Release Tablets

On August 11, 2021，Food and Drug Administration (FDA) approved SinoT’s ANDA（#213612）application for Paroxetine hydrochloride extended-release tablets（12.5mg,25mg）.

金太阳国际APP(中国)官方网站-IOS/Android版

ABOUT SINOT

Overview

Company Profile

Company Culture

Company History

R&D and Manufacturing

Contact Us

PRODUCTS

Launched Drug

Pending Approvals

CRO\CMO SERVICES

NEWS

CAREER

Talent Recruitment

Talent Development and Motivations

Staff activities

IR

Company news

Health Canada approves SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Health Canada approves SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

SinoT received tentative approval by FDA for Generic Tofacitinib Extended Release Tablet

FDA approves SinoT's ANDA application for PREGABALIN EXTENDED-RELEASE TABLETS

FDA approves SinoT’s ANDA application for Mesalamine, delayed-release tablets

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

The generic drug Posaconazole delayed-release tablets (100mg) Regulatory Approval in Singapore

NMPA approves SinoT’s ANDA application for Bupropion (XL)(150mg,300mg)

FDA approves SinoT’s ANDA application for PAROXETINE HYDROCHLORIDE，Extended-Release Tablets